Forsgren M F, Pine S, Harrington C R, Gregory D, Petersson M, Rinella M, (2024) Body composition and muscle composition phenotypes in patients on waitlist and shortly after liver transplant – results from a pilot study. BMC Gastroenterol; https://doi.org/10.1186/s12876-024-03425-2
Publication
Linking Sarcopenia, Brain Structure, and Cognitive Performance: A large-scale UK Biobank study
Gurholt P T, Germán Borda M, Parker N, Fominykh V, Kjelkenes R, Linge J, van der Meer D, Sønderby E I, Duque G, Westlye T L, Aarsland D, Andreassen A O, (2024), Linking Sarcopenia, Brain Structure, and Cognitive Performance: A large-scale UK Biobank study, Oxford Academic, https://doi.org/10.1093/braincomms/fcae083
Reduced Metabolic Flexibility is a Predictor of Weight Gain Among Liver Transplant Recipients
Bui AT, Chaudhari R, Bhati C, Wolver S, Patel S, Boyett S, Evans MC, Kamla H, Patel V, Forsgren M, Sanyal AJ, Kirkman D, Siddiqui MS, (2024) Reduced metabolic flexibility is a predictor of weight gain among liver transplant recipients, Liver Transplantation; https://doi.org/10.1097/LVT.0000000000000169
A rapid, non-invasive, clinical surveillance for CachExia, sarcopenia, portal hypertension, and hepatocellular carcinoma in end-stage liver disease: the ACCESS-ESLD study protocol
Nasr P, Forsgren M, Balkhed W, Jönsson C, Dahlström N, Simonsson C, Cai S, Cederborg A, Henriksson M, Stjernman H, Rejler M, Sjögren D, Cedersund G, Bartholomä W, Rydén I, Lundberg P, Kechagias S, Leinhard OD, Ekstedt M, (2023) A rapid, non-invasive, clinical surveillance for CachExia, sarcopenia, portal hypertension, and hepatocellular carcinoma in end-stage liver disease: the ACCESS-ESLD study protocol, BMC Gastroenterology, https://doi.org/10.1186/s12876-023-03093-8
Skewness in body fat distribution pattern links to specific cardiometabolic disease risk profiles
Linge J, Cariou B, Neeland IJ, Petersson M, Rodríguez Á, Leinhard OD, (2023), Skewness in body fat distribution pattern links to specific cardiometabolic disease risk profiles, JCEM, https://doi.org/10.1210/clinem/dgad570
Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients
Siddiqui MS, Parmar D, Shaikh F, Forsgren M, Patel S, Bui AT, Boyett S, Patel V, Sanyal AJ. (2023) Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients, Liver Transplantation, https://doi.org/10.1097/lvt.0000000000000110